Sharemaestro Newsreel

Beta Bionics, Inc. Stock 12‑Month Price Target Raised to $20.31, Implies 24% Upside

Beta Bionics, Inc. (BBNX) has seen its average 12-month price target raised from $20.08 to $20.31 by 11 analysts, with forecasts ranging from $14 to $30.4 per share. This new target implies a potential upside of approximately 24% from its August 10 closing price. …

908 Devices Q2 2026 slides: 23% growth, profitability in sight

908 Devices Inc. reported a 23% year-over-year revenue growth in Q2 2026, exceeding Wall Street expectations, with revenue reaching $16.1 million. The company is nearing profitability, with management raising full-year 2026 revenue guidance to $68 million-$70 million and projecting positive adjusted EBITDA of $0.7 …

AdaptHealth at Canaccord Genuity’s 46th annual growth conference: refocus deepens

AdaptHealth discussed its business transition at Canaccord Genuity's 46th Annual Growth Conference, focusing on organic growth, debt reduction, and core home medical equipment lines after divesting its diabetes business. The company highlighted strong sleep care demand and 16% Q2 2024 revenue growth, despite facing …

AdaptHealth (NASDAQ:AHCO) Trading Up 10.5% on Insider Buying Activity

AdaptHealth (NASDAQ:AHCO) saw its stock price increase by 10.5% due to significant insider buying activity, specifically by Director Kenneth A. Samet, who increased his holdings by 93.7% with a purchase worth nearly $150,000. Analyst sentiment is mixed but leans positive, with seven analysts rating …

NNOX Shareholder Alert: Nano-X Imaging Ltd. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for Nano-X Imaging Ltd. (NASDAQ: NNOX) investors, announcing a securities class action lawsuit. The lawsuit alleges that Nano-X Imaging Ltd. made materially false and misleading statements regarding its operational efficiency and product demand, leading to …

Portnoy Law Firm Announces Class Action on Behalf of Nano-X Imaging Ltd. Investors

The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Nano-X Imaging Ltd. (NASDAQ: NNOX) who purchased securities between March 31, 2025, and April 17, 2026. The lawsuit alleges that Nano-X overstated its efficiency, experienced misalignment between production and …

Important Notice to Long-Term Shareholders of Erasca, Inc.

Grabar Law Office is investigating potential breaches of fiduciary duties by officers and directors of Erasca, Insulet Corporation, Power Solutions International, and PROCEPT BioRobotics Corporation. The investigations stem from alleged misleading statements, manufacturing issues, and other concerns that led to stock declines for these …

Lost Money on PROCEPT BioRobotics Corporation (PRCT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

The Gross Law Firm has issued a notice to shareholders of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to join a class action lawsuit. The suit alleges that PROCEPT BioRobotics Corporation made false or misleading statements regarding an undisclosed discount program that inflated sales and revenue, …

AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth

Key Points Interested in AdaptHealth Corp.? Here are five stocks we like better. AdaptHealth is selling its roughly $600 million diabetes business to Cardinal Health and exiting certain e-commerce and drop-ship operations to simplify the company and focus on sleep, respiratory and home medical …

908 Devices (NASDAQ:MASS) Announces Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Neuronetics (NASDAQ:STIM) Announces Earnings Results

Understanding the Setup: (KIDS) and Scalable Risk

This article provides an in-depth analysis of Orthopediatrics Corp. (NASDAQ: KIDS), highlighting a potential long-term breakout if current strong sentiment holds. It offers AI-generated signals, institutional trading strategies tailored to different risk profiles, and a multi-timeframe signal analysis to guide investors. Key findings indicate …

New AffloVest airway therapy launch narrows Tactile Medical outlook

Tactile Systems Technology (Nasdaq: TCMD) reported Q2 2026 revenue of $85.7 million, a 9% year-over-year increase, driven primarily by lymphedema product sales, though airway clearance revenue saw a 7% decline due to inventory adjustments from the new AffloVest launch. The company's net income more …

Quanterix 2Q Rev $32.9M >QTRX

This article provides a brief update on Quanterix's Q2 revenue. The company reported revenue of $32.9 million, surpassing analyst expectations. This financial update indicates a positive performance for Quanterix during the second quarter.

Boston Scientific Stock And 2 Low Volatility Picks For A Slower US Economy

Amidst growing concerns about a slower U.S. economy, this article identifies three low-volatility stocks—Boston Scientific (BSX), Aon (AON), and CorVel (CRVL)—that are well-positioned for resilience. Boston Scientific benefits from essential medical procedures, Aon from its risk management services, and CorVel from its debt-free status …

GE HealthCare Technologies (GEHC) Just Overtook the 200-Day Moving Average

GE HealthCare Technologies (GEHC) has surpassed its 200-day moving average, signaling a potential long-term bullish trend. The stock has risen 11.7% in the past four weeks and holds a Zacks Rank #3 (Hold), supported by positive earnings estimate revisions. Investors are encouraged to monitor …

GE HealthCare Technologies Inc. (GEHC) latest stock news and headlines

This article provides a compilation of recent news and headlines regarding GE HealthCare Technologies Inc. (GEHC), detailing its stock performance, financial updates, and product innovations. It highlights GEHC's stock activity, including recent movements and performance against the S&P 500, alongside reports on strong Q2 …

Why is Abbott Laboratories stock gaining today?

Abbott Laboratories stock rose 1.2% after announcing a multi-year collaboration with Google Health. This partnership will integrate glucose data from Abbott's Lingo biowearable continuous glucose monitor into the Google Health app, offering personalized health recommendations. The deal also includes a large-scale metabolic health study, …

Earnings call transcript: Neuronetics tops Q2 2026 forecasts as stock jumps 23%

Rapid Micro Biosystems (RPID) Receives a Buy from Lake Street

Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know

Have you looked into how Haemonetics (HAE) performed internationally during the quarter ending June 2026? Considering the widespread global presence of this provider blood management systems for health care providers and blood collectors, examining the trends in international revenues is essential for assessing its …

ALAMAR BIOSCIENCES INC : STIFEL RAISES TARGET PRICE TO $32 FROM $28

Stifel has increased its target price for ALAMAR BIOSCIENCES INC to $32 from $28. This update, reported by Reuters, reflects an analyst's revised valuation for the company. The article emphasizes that the content represents the author's opinion and should not be used as investment …

Avita Medical Target Price Raised 52% to A$1.90/Share by Canaccord Genuity>AVH.AU

Canaccord Genuity has increased its target price for Avita Medical (AVH.AU) by 52%, setting a new target of A$1.90 per share. This upgrade suggests a strong positive outlook from the analyst firm regarding Avita Medical's future performance.

Neuronetics publishes investor presentation on NeuroStar TMS, Greenbrook clinic network strategy

Neuronetics has released an investor presentation detailing its NeuroStar TMS and Greenbrook clinic network strategy. The company provided FY 2026 revenue guidance of $160 million to $164 million, projecting 7% to 10% year-on-year growth, alongside a gross margin outlook of 48% to 50%. It …

Neuronetics STIM Draws Buy Rating As Vertical Psychiatry Platform Scales Up

Neuronetics (STIM) has received a "Buy" rating and a $5 target price from BTIG, signaling bullish sentiment due to its expanding depression-treatment technology adoption and vertically integrated psychiatry platform. The company's acquisition of 93 Greenbrook-operated treatment centers and the establishment of a National Center …

Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations

Vivos Therapeutics is expanding its partnership with Greenway Health to implement the AI-by-design Novare platform across its clinical and revenue operations, starting with Sleep Centers of Nevada. This collaboration aims to generate significant annual value through increased patient capacity, improved revenue cycles, and substantial …

Vivos AI rollout could recover an estimated 46,000+ work hours in Nevada

Vivos Therapeutics is expanding its partnership with Greenway Health to deploy the AI-by-design Novare platform across its clinical and revenue operations, starting with Sleep Centers of Nevada (SCN). This initiative is estimated to generate about $9.1 million in annual value for Vivos at SCN, …

Nano-X Imaging (NNOX) CEO Erez Meltzer adds 9,443 shares via owned company

Nano-X Imaging Ltd. CEO Erez Meltzer indirectly purchased 9,443 Ordinary Shares on August 10, 2026, at $1.03 per share through his wholly-owned company, Oud Nof. This transaction increased Oud Nof's holdings to 45,443 shares, while Meltzer also directly holds 60,584 Ordinary Shares and multiple …

The Number One Reason I Keep Buying Intuitive Surgical Now For The Long Run

Quick Read ISRG is down 31% YTD, but its razor-and-razorblade model now delivers 85% recurring revenue across a fleet of 11,710 da Vinci systems. MDT's Hugo and JNJ's Ottava remain early or pre-commercial, leaving ISRG's $1.73 billion quarterly instruments-and-accessories stream with no real soft-tissue …

Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI

Abbott and Google Health have announced a multi-year partnership to integrate glucose insights from Abbott's Lingo biowearable with Google's AI and consumer technology. This collaboration aims to provide personalized metabolic insights through the Google Health app, helping users understand how daily behaviors affect their …

Adagio Medical (NASDAQ: ADGM) posts Q2 2026 loss and warns on cash runway

Abbott, Google to Study How Sleep and Activity Affect Glucose

Abbott has announced a multi-year partnership with Google Health to integrate insights from Abbott's Lingo continuous glucose monitor with Google's AI and consumer technology. This collaboration aims to provide personalized metabolic insights through the Google Health app, offering AI-powered guidance on nutrition, activity, sleep, …

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates

Form 8K Adagio Medical Holdings Inc For: 11 August By Investing.com

This article announces that Adagio Medical Holdings Inc. has filed a Form 8K for August 11. The filing is related to the company's financial activities and is reported by Investing.com.

Adagio Medical reports Q2 2026 net loss of $6.7M, cash $7.7M

Adagio Medical reported a net loss of $6.7 million for Q2 2026 with no revenue, and ended the quarter with $7.7 million in cash. The company highlighted positive results from its FULCRUM-VT trial and the first patient treatment with its next-generation vCLAS Ultra catheter, …

Adagio Medical Holdings, Inc. 2026: Revenue $4.93M, EPS ($0.3) — 10-Q Summary

Adagio Medical Holdings, Inc. reported its 2026 quarterly results, with revenue reaching $4.93M and a diluted loss per share of ($0.3). The company announced significant business highlights, including completing enrollment for the FULCRUM-VT pivotal IDE study, submitting a PMA for vCLAS, and launching the …